Publication: Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report
Date
2021
Journal Title
Journal ISSN
Volume Title
Publisher
Nepal Medical Association
Abstract
Abstract:
Severe coronavirus disease 2019 can be associated with progressive respiratory failure. In addition to respiratory support and other supportive care, use of corticosteroids has shown to improve outcome. Despite the use of steroids, a significant proportion of patients progressively worsen. Adjunct immunomodulators have been studied in addition to steroids in these patients. Here we present a successful use of tofacitinib, a Janus Kinase inhibitor, in conjunction with dexamethasone for a patient with rapid worsening of respiratory status and with high level of serum inflammatory biomarkers.
Description
Gentle Sunder Shrestha
Department of Anaesthesiology, Tribhuvan University Teaching Hospital, Kathmandu
Bidesh Bista
Department of Internal Medicine, Civil Service Hospital of Nepal, Kathmandu, Nepal
Ashesh Dhungana
Department of Internal Medicine, National Academy of Medical Sciences, Bir Hospital, Kathmandu, Nepal
Nimesh Poudel
Department of Internal Medicine, Kathmandu Medical College and Teaching Hospital, Kathmandu, Nepal
Shraddha Bhattarai
Department of Critical Care Medicine, Alka Hospital Pvt. Ltd, Lalitpur, Nepal
Manjit Shrestha
Department of Critical Care Medicine, Alka Hospital Pvt. Ltd, Lalitpur, Nepal
Sandip Bhandari
Department of Anaesthesiology, Shahid Gangalal National Heart Centre, Kathmandu, Nepal
Binit Vaidya
Department of Rheumatology, National Center for Rheumatic Diseases, Kathmandu, Nepal
Keywords
COVID-19, dexamethasone, immunomodulation